Dr Reddy's Labs to commercialize Ingenus Pharma cancer injection Cyclophosphamide in US

Hyderabad: Dr Reddy's Laboratories, Inc., a step down wholly owned subsidiary of the Company (referred to hereinafter as "Dr. Reddy's USA"), and Ingenus Pharmaceuticals, LLC, a Delaware limited liability company, (“Ingenus”), have entered into license agreement pursuant to which Dr. Reddy’s USA has licensed from Ingenus, the exclusive rights to commercialize Cyclophosphamide Injection RTD (500 mg/2.5mL; 1g/5mL; 2g/10mL) for cancer treatment in the United States.

Under the in-licensing pact, Dr. Reddy’s USA to in-license and commercialize for the U.S. market. Dr. Reddy’s USA shall pay to Ingenus 50% of the calculated profit share and no other consideration is payable.

The sales of the said Ingenus product as per the IQVIA for the past 12 months ended March 2024 was $51.8 million.

The NDA covering the product will be assigned to Dr. Reddy’s USA. The parties will enter into a commercial supply agreement pursuant to which Ingenus will supply the product to Dr. Reddy’s USA.

Read also: Conduct Phase III CT: CDSCO panel tells Dr Reddy's Labs after noting Dutasteride linked with AEs like sexual impotence

Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The Company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Dr Reddy's Labs major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. 

Read also: Dr Reddy's Labs arm Aurigene Pharma inaugurates biologics facility in Genome Valley